Delegate of the Board and Chief Executive Officer of SynDermix AG, Mr. Dieter Hemmer, on medical leave of absence; Dr. Konstantinos Efthymiopoulos appointed Designated Managing Director until the AGM 2020
(more…)
SynDermix is a Swiss developer of innovative health technologies that focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.
SynDermix Announces Interim Changes to Leadership 20 May, 2020 in UpdatesDelegate of the Board and Chief Executive Officer of SynDermix AG, Mr. Dieter Hemmer, on medical leave of absence; Dr. Konstantinos Efthymiopoulos appointed Designated Managing Director until the AGM 2020
(more…)
Update on the Clinical Trial of the SDX-3101 Medical Device 7 April, 2020 in UpdatesSynDermix AG announced temporary postponement of initiation of the SDX-3101 clinical trial on chronic rhinosinusitis without nasal polyps due to the novel coronavirus pandemic. (more…)
First Site Initiation Visit (SIV) Completed for the Clinical Trial of SDX-3101 in Austria 7 January, 2020 in UpdatesSynDermix AG is pleased to announce the successful completion of the first SIV for the clinical trial of SDX-3101, in preparation for the recruitment of the first patient to the study. (more…)
SDX-31 is an electronic medical device platform based on Precisely Modulated Acoustic Energy™ (PMAE) therapy; a proprietary type of treatment during which digitally controlled acoustic frequencies are generated
SDX-21 is a platform based on an endogenous Nitric Oxide (NO) donor in an easy-to-use formulation, which can be leveraged for the development of drug products or medical devices, depending on the selected indication
SDX-13 is a drug platform based on a novel recombinant plant lectin with positive Phase IIa results in epithelial healing and a favourable safety profile
Together, our executive team, specialist partners and company values combine to sustain ground-breaking health science and process excellence.
SynDermix is a privately funded company. Investors and other account holders, please click here to log in.
